Tonix Pharmaceuticals Holding Corp. TNXP shares are trading higher Monday after the company secured a second commercial payer agreement for TONMYA, its recently launched fibromyalgia treatment. Tonix ...

Tonix remains rated Hold as Tonmya's commercial launch underwhelms, with Q1 2026 net product revenue at $3.7m. Read more on ...

Find the latest Tonix Pharmaceuticals Holding Corp. (TNXP) stock quote, history, news and other vital information to help you with your stock trading and investing.

Tonix Pharmaceuticals (TNXP) shares gained on Monday after the firm announced a crucial update to its fibromyalgia treatment, Tonmya, which expands coverage to roughly 52 million people in the U.S.

Tonix Pharmaceuticals (TNXP) stock and MapLight Therapeutics (MPLT) stock gains as Raymond James issues them new Strong Buy ...

View Tonix Pharmaceuticals Holding Corp. TNXP stock quote prices, financial information, real-time forecasts, and company news from CNN.

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are trading higher Friday after the company announced the United States Patent and Trademark Office granted a patent covering the subcutaneous ...

) has been revised to $55.42 / share. This is a decrease of 15.76% from the prior estimate of $65.79 dated April 12, 2026. The price target is an average of many targets provided by analysts. The ...

Tonix Pharmaceuticals shares are trading lower by 7.2% Monday. The company last week announced the pricing of a $4.4 million registered direct offering. Get the exact trades and sectors to target ...